ACAAI年会研究:儿童生物制剂从处方到获批平均耗时32.65天,近四成预授权被拒
ACAAI: Considerable delay seen from Rx to approval for children's biologics
美国ACAAI年会显示,儿童生物制剂从处方到最终批准平均需32.65天,约39.3%需预先授权的处方遭拒。该回顾性研究纳入326例处方(2018–2026年),最常用药物为omalizumab(55.8%),其次为dupilumab(26%)。PA被拒最常见原因是不符合保险标准(24.4%)及需先尝试其他药物(23.4%)。
There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual meeting of the American College of Allergy, Asthma and Immunology, held from Nov. 12 to 16 in Phoenix.
Mark Holland, M.D., from the Children's Mercy Hospital in Kansas City, Missouri, and colleagues examined the landscape of PA denials of biologic therapies by payers in a retrospective chart review of pediatric patients (median age, 11.4 years; 50.3% male and 49.7% female) who had been prescribed biologics by allergists for atopic conditions. The analysis included omalizumab, mepolizumab, benralizumab, dupilumab and tezepelumab, which were prescribed between 2018 and 2026.
The researchers identified 326 prescriptions for biologic therapy. The most frequently prescribed biologic was omalizumab, which accounted for more than half of the biologics prescribed (55.8%), followed by dupilumab (26%). Overall, 39.3% of the prescriptions requiring a PA were denied. Not meeting insurance criteria and a trial of a prerequisite were the most common reasons for denial (24.4% and 23.4%, respectively). There was a mean of 32.65 days from prescription of medication to approval.
"We hope this data helps start a conversation about making the approval process faster and simpler," co-author Aarti Pandya, M.D., also from the Children's Mercy Hospital, said in a statement. "Children shouldn't have to wait weeks for care their allergist knows they need immediately."
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Copyright © 2026 HealthDay. All rights reserved.
Citation: ACAAI: Considerable delay seen from Rx to approval for children's biologics (2026, November 16) retrieved 16 November 2026 from https://medicalxpress.com/news/2026-11-acaai-considerable-delay-rx-children.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com